+1(804) 937-3321
info@onecallpharmacy.com
$79.99
The return of a legendary PH
Goal: Build Muscle
Lean, dry muscle gains – no water retention or bloat
Dramatic strength increases in the gym
No conversion to oestrogen, anti-oestrogenic properties
Less severe side effects than other, harsher prohormones
The option to stack with a non-methylated PH
IGF-1 LR3 (Insulin-like Growth Factor 1, Long R3) is a synthetic peptide engineered for prolonged anabolic activity.5 With a significantly longer half-life than natural IGF-1, it delivers extended stimulation for cell growth, muscle hypertrophy, and fat metabolism, making it a favorite among advanced researchers and elite athletes.6 Buy IGF-1 LR3 Peptide 🛒
This peptide is primarily studied for its powerful effects on body composition and recovery:
Stimulates muscle hyperplasia (creation of new muscle cells) and hypertrophy (growth of existing cells) 💪.
Increases lean muscle mass and strength.
Accelerates fat burning 🔥 and tissue recovery.
Promotes cellular regeneration.
Improves endurance and training response 🏃.
| Feature | Mechanism | Implication for Research |
| Action | IGF-1 LR3 mimics insulin and directly stimulates muscle tissue growth. | The primary mediator for the anabolic effects of Growth Hormone (GH). |
| Half-Life | Approximately 20–30 hours 🕰️ (significantly longer than native IGF-1). | Highly effective for extended anabolic activity and less frequent dosing. |
| Potency | Modified structure results in very low binding affinity to IGF-binding proteins. | This allows the peptide to circulate freely in the bloodstream, increasing potency. |
Typical Doses: 20–50 mcg per day.
Method: Injected subcutaneously or intramuscularly post-workout (preferred timing).
Cycle Duration: Common cycles last 4–6 weeks.
CJC-1295 Peptide
Tesamorelin HGH Support
Peptides for Muscle Growth
Human Growth Category
Disclaimer: IGF-1 LR3 is intended for research purposes only. Not for human consumption unless prescribed by a licensed medical professional. 🧪
Reviews
There are no reviews yet.